2022 American Transplant Congress
A Single-Center’s Outcomes of Combined Heart-Liver Transplantation
*Purpose: The purpose of this study was to evaluate rejection outcomes in our combined heart-liver transplant (CHLT) recipients at 6 months.*Methods: This is a retrospective,…2022 American Transplant Congress
SARS-CoV-2 Antibody Response by mRNA Vaccine Platform in Incrementally Immunosuppressed Patients
1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: This study compares SARS-CoV-2 antibody responses between the two-dose mRNA-1273 and BNT162b2 vaccine series across groups of incrementally immunosuppressed patients.*Methods: Semiquantitative testing for antibodies…2022 American Transplant Congress
Understanding The Modification Of Eplet Mismatch Risk By Immunosuppression Regimen
*Purpose: Solid organ transplant donor-recipient eplet mismatch has been correlated with subsequent donor specific antibody (DSA) formation, antibody mediated rejection, and overall rejection rates. However,…2022 American Transplant Congress
BK Viremia in Living vs Deceased Donor Renal Transplant Recipients Receiving Alemtuzumab Induction
1University of Maryland Medical Center, Baltimore, MD, 2Univ of Maryland Schl of Med, Baltimore, MD
*Purpose: There is conflicting data regarding the association of donor type and BK viremia in renal transplant recipients. This study sought to compare the incidence…2022 American Transplant Congress
Protective Immunity Against a Murine Epstein-Barr Virus Homolog is Preserved During CD11b-CD154 Blockade
Emory University Transplant Center, Emory University, Atlanta, GA
*Purpose: CD154 pathway antagonism has shown to be a promising target for inducing long-time graft survival, in some cases showing efficacy that is superior to…2022 American Transplant Congress
External Validation of the Abbreviated Ibox Scoring System at One-Year Post Kidney Transplant as a Surrogate Endpoint for Death-Censored Graft Survival
*Purpose: The Transplant Therapeutics Consortium seeks to translate the iBox from Loupy et al., 2019 into a surrogate endpoint for five-year death-censored graft survival after…2022 American Transplant Congress
Low Fixed Tacrolimus Starting Dose and the Correlation with Renal Allograft Rejection
David Geffen School of Medicine, Los Angeles, CA
*Purpose: Achieving a tacrolimus therapeutic trough concentration (C0) by post-operative day (POD) 3-7 has been associated with a reduced risk for rejection. Although FDA prescribing…2022 American Transplant Congress
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation
*Purpose: The new kidney allocation system has caused increased organ travel times and therefore increased cold ischemia time. Furthermore, the change in the priority to…2022 American Transplant Congress
Pegloticase Use in Renal Transplant Recipients with Gout: Findings from an Insurance Claims Database Study
1Iowa Kidney Physicians, Des Moines, IA, 2Horizon Therapeutics plc, Deerfield, IL
*Purpose: Kidney transplant (KT) recipients have high gout incidence due to reduced eGFR and medication use associated with hyperuricemia.1 Oral urate-lowering therapies in KT patients…2022 American Transplant Congress
Comparing The Immunologic Responses Between Kidney Transplant Recipients Receiving Standard Immunosuppression And CNI Reduction After Two Doses Of ChAdOx-1 And A Booster Dose BNT162b2
*Purpose: Immunosuppression can impair immunological responses after vaccination in kidney transplant recipients (KTR). However, little is known about the effect of the booster dose of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 138
- Next Page »